Skip to main content
    S

    Standard Biotools Inc (LAB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.66
    +0.00 (+0.17%)

    Market Cap: $260.28M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -55.56%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.04+42.9%
    60d ago$-0.04+42.9%
    30d ago$-0.04+42.9%
    7d ago$-0.04+42.9%
    Current$-0.02
    Revenue Consensus
    $19M
    Range$19M - $19M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.03 - $-0.03
    1 analysts
    Revenue Consensus
    $25M
    Range$25M - $25M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 5
    		$-0.05$-0.03-66.67%Miss-25.0%
    Mar 26
    Reported May 5
    		$-0.02$-0.02+0.00%Beat+60.0%
    Dec 25
    Reported Feb 24
    		$0.07$-0.05+226.08%Beat+236.0%
    Sep 25
    Reported Nov 4
    		$-0.04$-0.02-100.00%Miss-33.3%
    Jun 25
    Reported Aug 11
    		$-0.04$-0.04+0.00%Beat+50.0%
    Mar 25
    Reported May 6
    		$-0.05$-0.04-25.00%Miss+79.2%
    Dec 24
    Reported Feb 26
    		$-0.05$-0.03-64.67%Miss+80.2%
    Sep 24
    Reported Oct 30
    		$-0.03N/A+57.14%Beat+78.6%
    Jun 24
    Reported Jul 31
    		$-0.08$-0.07-14.29%Miss+42.9%
    Mar 24
    Reported May 8
    		$-0.24$-0.10-140.00%Miss-14.3%
    Dec 23
    Reported Feb 28
    		$-0.25$-0.13-92.31%Miss+3.8%
    Sep 23
    Reported Nov 7
    		$-0.14$-0.12-16.67%Miss+62.2%
    Jun 23
    Reported Aug 8
    		$-0.14$-0.10-40.00%Miss+57.6%
    Mar 23
    Reported May 9
    		$-0.21$-0.06-250.00%Miss+16.0%
    Dec 22
    Reported Feb 14
    		$-0.26$-0.28+7.14%Beat-116.7%
    Sep 22
    Reported Nov 8
    		$-0.37$-0.13-184.62%Miss-428.6%
    Jun 22
    Reported Aug 8
    		$-0.33$-0.15-120.00%Miss-175.0%
    Mar 22
    Reported May 5
    		$-0.25$-0.18-38.89%Miss-66.7%
    Dec 21
    Reported Feb 17
    		$-0.12N/A+57.14%Beat+7.7%
    Sep 21
    Reported Nov 8
    		$-0.07$-0.11+36.36%Beat-333.3%
    Jun 21
    Reported Aug 5
    		$-0.12$-0.08-50.00%Miss-71.4%
    Mar 21
    Reported May 6
    		$-0.15$-0.04-275.00%Miss-15.4%
    Dec 20
    Reported Feb 10
    		$-0.13$0.01-1400.00%Miss-333.3%
    Sep 20
    Reported Nov 5
    		$0.03N/A+127.27%Beat+133.3%
    Jun 20
    Reported Aug 6
    		$-0.07$-0.14+50.00%Beat+30.0%
    Mar 20
    Reported May 7
    		$-0.13$-0.10-30.00%Miss+7.1%
    Dec 19
    Reported Feb 10
    		$-0.03N/A+66.67%Beat+50.0%
    Sep 19
    Reported Nov 5
    		$-0.09$-0.09+0.00%Beat+30.8%
    Jun 19
    Reported Aug 1
    		$-0.10$-0.07-42.86%Miss+56.5%
    Mar 19
    Reported May 2
    		$-0.14$-0.10-40.00%Miss+33.3%
    Dec 18
    Reported Feb 7
    		$-0.06N/A+68.42%Beat+60.0%
    Sep 18
    Reported Nov 1
    		$-0.13$-0.18+27.78%Beat+48.0%
    Jun 18
    Reported Aug 2
    		$-0.23$-0.23+0.00%Beat+25.8%
    Mar 18
    Reported May 3
    		$-0.21$-0.30+30.00%Beat+36.4%
    Dec 17
    Reported Feb 8
    		$-0.15$-0.25+40.00%Beat+53.1%
    Sep 17
    Reported Nov 2
    		$-0.25$-0.31+19.35%Beat-
    Jun 17
    Reported Aug 3
    		$-0.31$-0.34+8.82%Beat-
    Mar 17
    Reported May 4
    		$-0.33$-0.56+41.07%Beat-
    Dec 16
    Reported Feb 8
    		$-0.32$-0.23-39.13%Miss-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-15.39EV/EBITDAN/A
    Price/FCF-3.12xFCF Yield-32.06%
    Profitability
    Profit Margin100.40%Operating Margin-38.90%
    ROE-11.20%ROIC-12.05%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio9.10xQuick Ratio8.80x
    Trading Statistics
    Beta1.35Avg Volume957.28K
    52-Week High$1.7252-Week Low$0.63

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.71
    SMA 20$0.72
    SMA 50$0.71
    SMA 200$0.97
    EMA 10$0.69
    EMA 20$0.71
    EMA 50$0.73
    EMA 200$0.92

    MACD

    Line: -0.01Signal: -0.00Hist: -0.01

    ADX

    ADX: 16.4+DI: 16.9-DI: 22.3

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down88.0
    PSAR$0.78

    Bollinger Bands

    Upper Band$0.79
    Lower Band$0.65
    %B Position1854%(Upper)
    Band Width0.04

    RSI (14-Day)

    Neutral
    39.3

    Momentum Oscillators

    Stoch %K18.3
    Stoch %D18.9
    Williams %R-87.8
    ROC (10d)-7.6%
    Momentum-0.05
    CCI (20d)-165.8
    MFI (14d)48.8

    Volatility Measures

    ATR (14d)$0.04(6.4%)
    StdDev (20d)0.03
    Hist Vol50.4%(High)

    Volume Flow

    VWAP$0.66
    OBV-1.7M
    AD Line-62.1M
    CMF (20d)0.011

    Volume Metrics

    Avg Vol (20d)976.1K
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.73

    Pivot Points

    R3$0.72
    R2$0.71
    R1$0.68
    Pivot Point$0.67
    S1$0.64
    S2$0.63
    S3$0.60

    Advanced Oscillators

    TSI-9.32
    Ultimate Osc34.9
    KST19.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.10M$21.15M$3.22M$19.55M$21.76M$20.22M$890,000$22.09M$22.49M$45.54M$28.19M$25.37M
    Cost of Revenue$9.57M$9.84M$532,000$10.07M$11.13M$9.17M$2.69M$9.96M$12.12M$21.35M$14.78M$14.21M
    Gross Profit$10.54M$11.31M$2.69M$9.48M$10.63M$11.05M$-1,805,000$12.13M$10.37M$24.19M$13.41M$11.15M
    Operating Expenses$35.92M$23.80M$21.33M$42.42M$36.33M$38.02M$8.54M$38.83M$40.63M$84.37M$34.80M$32.33M
    R&D$1.98M$2.12M$2.08M$6.36M$6.22M$5.44M$-1,332,000$6.94M$7.24M$15.98M$6.96M$6.37M
    SG&A$16.39M$18.61M$16.45M$26.59M$28.11M$29.82M$6.79M$24.47M$24.86M$46.94M$21.35M$22.29M
    Operating Income$-25,388,000$-12,496,000$-18,644,000$-32,938,000$-25,697,000$-26,970,000$-10,343,000$-26,699,000$-30,261,000$-60,182,000$-21,386,000$-21,172,000
    Interest Income$4.61M$3.51M$1.66M$2.14M$2.45M$2.91M$3.90M$4.79M$5.30M$6.21M$4.92M$340,000
    Interest Expense$0$2.12M$5,000$10,000$0$0$572,000$853,000$858,000$1.03M$0$0
    Income Before Tax$-21,435,000$-14,615,000$-19,336,000$-32,900,000$-18,282,000$-23,489,000$-11,162,000$-21,801,000$-25,405,000$-32,029,000$-19,938,000$-20,947,000
    Income Tax Expense$90,000$11,000$-35,900,000$-1,216,000$-609,000$-119,000$257,000$118,000$39,000$128,000$-162,000$50,000
    Net Income$-26,758,000$127.07M$19.28M$-34,687,000$-33,459,000$-26,033,000$-34,072,000$-26,938,000$-45,718,000$-32,157,000$-19,776,000$-20,997,000
    EBITDA$-25,980,000$-17,350,000$-20,164,000$-34,120,000$-17,470,000$-23,073,000$-11,665,000$-23,643,000$-27,877,000$-34,669,000$-17,321,000$-17,471,000
    EBIT$-26,046,000$-18,126,000$-20,993,000$-35,030,000$-20,734,000$-26,403,000$-14,486,000$-25,742,000$-29,849,000$-37,203,000$-20,287,000$-21,287,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LAB

    Government Contracts

    Gov Obligations (TTM)
    $849995
    Gov Obligations / Revenue
    1.0%
    Obligations YoY
    N/A
    Active Awards
    11
    New Awards (TTM)
    5
    Avg Remaining Term
    2.3 mo

    Top agency: Department of Health and Human Services at 63.1% of trailing twelve month obligations across 5 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N94025P00585Department of Health and Human ServicesNational Institutes of Health$507000Sep 10, 2025
    1232SA25P0235Department of AgricultureAgricultural Research Service$136842Aug 21, 2025
    68HE0B25P0717Environmental Protection AgencyEnvironmental Protection Agency$35678Sep 10, 2025
    140FS126P0051Department of the InteriorU.S. Fish and Wildlife Service$15117Feb 26, 2026
    75N92B25P00247Department of Health and Human ServicesNational Institutes of Health$13797Sep 25, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Standard Biotools Inc (LAB-Q) Stock Price and News

    This article provides detailed stock information for Standard Biotools Inc (LAB-Q), including real-time stock price, daily performance metrics...

    The Globe and Mail•10/7/26•Somewhat-Bullish

    Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.com

    Standard BioTools Inc. has announced a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare. This transaction is anticipated to close in approximately 30...

    Investing.com Nigeria•10/6/26•Neutral

    Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.com

    Standard BioTools Inc. has announced the sale of its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare industries. This transaction is another step in Standard BioTools' strategic actions...

    Investing.com South Africa•10/6/26•Neutral

    Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

    Standard BioTools Inc. announced its definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare investment firm. This transaction, expected to close in approximately 30 days...

    GlobeNewswire•10/6/26•Bullish

    Standard BioTools to Sell Microfluidics Business to Archimed

    Standard BioTools has announced its intention to sell its microfluidics business to Archimed. The financial terms of the deal were not disclosed in this announcement. This transaction marks a strategic move for Standard...

    Genome Web•10/6/26•Neutral

    LAB Valuation and Fair Value

    P/E
    -15.4x
    P/FCF
    -3.1x
    P/B
    0.5x
    See GNG's fair value

    LAB Profitability: Margins, ROIC and FCF

    Gross margin
    53.1%
    Operating margin
    -38.9%
    Net margin
    100.4%
    ROIC
    -12.1%
    ROE
    -11.2%
    FCF margin
    -129.0%
    FCF yield
    -32.1%

    LAB Competitors

    CompanyTicker
    Nautilus Biotechnology IncNAUT
    Palisade Bio IncPALI
    Treace Medical Concepts IncTMCI
    Prelude Therapeutics IncPRLD
    InfuSystems Holdings IncINFU
    EyePoint, IncEYPT
    Anika Therapeutics IncANIK
    OraSure Technologies IncOSUR

    Sector: Healthcare

    LAB Bull Case vs Bear Case

    Bull case

    • LAB has a 100.4% net profit margin.

    Bear case

    • LAB beat EPS estimates in 25.0% of its last 8 reported quarters.
    • LAB's quarterly revenue changed -7.6% year over year.

    LAB Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    3.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    LAB Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About LAB

    Does LAB pay dividends?

    Standard Biotools Inc (LAB) has a dividend payment track record. See the LAB dividend history page for its current payment status, TTM yield, and recorded payments.

    What is LAB's market cap?

    Standard Biotools Inc (LAB) has a market capitalization of $260.28M with a current stock price of $0.66.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In